Combining serology & viral nucleic acid tests in a single device, this innovation will facilitate rapid Point-of-Care triage and patient treatment, new biomarker discovery for drug development, and home self tests for health monitoring.

Altratech will be exhibiting at the Tri Con Conference in San Francisco on 4–5 May 2026, booth 5. During the conference, Dr Tara Dalton, CEO of Altratech, will present data from a March 2026 pre‑clinical study involving HIV patient samples.